Update on December transits to IPIX.
FM 8 Gemini
NM 23 Sagittarius
Dates below can be +/- 1 day. If company is aware of the news on a weekend, it may not be made known as PR until Monday. So if transit is for a Friday, PR will probably be on a Monday.
12/4 Transit Sun conjunct Natal Jupiter 13 Sag activates natal Venus trine Jupiter in the chart:
This highlights news involving publishing and dealings with foreign countries or groups representing foreign countries. Therefore, possible news about peer review, info on trials in foreign countries, negotiations regarding partnerships/collaboration.
12/9 Transit Mercury conjunct natal Jupiter. More articles being written about Brilacidin and IPIX. More news from the company.
12/12/ T Sun 21 Sag aspecting N Neptune 21 Aquarius. T Mercury trine natal Venus/Saturn. T Mars 21 Aries trine natal Saturn 21 Leo. T Venus in a Yod formation to N Sun and N Mars. There is so much activity in the chart with these transits, things should start to move forward with IPIX and B. Possible timetables on dates and locations of trials.
The following dates have things progressing with the feeling by the end of the month that finally the stalemate is over.
12/15 through 12/18 T Mars trine N Saturn exact at same time in exact aspect to Neptune (one of its rulerships is drugs) at 21 Aquarius. T Sun trine Mars activating N Mars Trine Pluto.
12/28 to 12/31 T Mars 26 Aries conjunct N Mars 25 Aries trine N Pluto
26 Sag. Drug trials may actually commence before years' end giving people much more confidence in IPIX. Transits from Mars indicate action, activity, an undertaking of a plan. Mars is not an idle planet. However, it was in retrograde phenomenon for 3 months at a time when all were expecting to be further ahead on the timetable than the company was. So from end of August to end of November delays were more than obvious and possibly due to a variety of reasons: the election and politics, the inefficiency of agencies involved with drug approvals, the manipulation of BPs through their ability to influence the agencies involved with drug approvals. Would Gilead have overfilled its coffers from remdesivir if Brilacidin was pole vaulted through the IND approval process so that human trials could have begun much sooner with resultant news lowering remdesivir's phenominal financial gains that they made during the 3 months that Brilacidin seemed to be at a standstill. And surely there are other BPs who will be affected by B's lab testing revealing that it can be used to hammer all coronaviruses to a pulp thus affecting some of the drugs BPs currently have on the market. One example is Tamiflu which I don't think helps the flu to any great extent but has made a lot of money for the BP that owns it. Now you have Brilacidin which will probably work better and cost less. These are just my opinions.
After looking ahead into 2021 with IPIX chart, exciting times are ahead, IMO!
